欧美牲交a欧美牲交aⅴ免费下载 ,国产乱码精品一区二区三区四川人

Polifeprosan 20

NMR下載 COA and HPLC MSDS下載
names：
4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (11)
CAS號(hào)：
90409-78-2
MDL Number：
MF(分子式)： C27H34O10 MW(分子量)： 518.56
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢(xún)價(jià) 提供各種包裝，敬請(qǐng)垂詢(xún)
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車(chē) 立即購(gòu)買(mǎi)

快速詢(xún)價(jià)

收起

你想詢(xún)價(jià)的產(chǎn)品

*產(chǎn)品名稱(chēng)：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱(chēng)：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢(xún)價(jià)

中文別名	4,4'-(propane-1,3-diylbis(oxy))dibenzoic acid compound with decanedioic acid (11)
英文別名	Polifeprosan 20; Polifeprosan; Polifeprosanum.
CAS號(hào)	90409-78-2
Inchi	InChI=1S/C17H16O6.C10H18O4/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;11-9(12)7-5-3-1-2-4-6-8-10(13)14/h2-9H,1,10-11H2,(H,18,19)(H,20,21);1-8H2,(H,11,12)(H,13,14)
InchiKey	JVYNJRBSXBYXQB-UHFFFAOYSA-N
分子式 Formula	C27H34O10
分子量 Molecular Weight	518.56
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說(shuō)明	Polifeprosan 20(CAS:90409-78-2):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類(lèi)或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。
Introduction	Polifeprosan 20 is biodegradable polymeric matrix that can be surgically implanted for the interstitial delivery of drugs, such as BCNU, in the brain.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Kleinberg L. Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. Patient Prefer Adherence. 2016 Nov 24;10:2397-2406. eCollection 2016. Review. PubMed PMID: 27920506; PubMed Central PMCID: PMC5125766.

[2]Kleinberg L. Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide. Core Evid. 2012;7:115-30. doi: 10.2147/CE.S23244. Epub 2012 Oct 26. PubMed PMID: 23118709; PubMed Central PMCID: PMC3484478.

[3] Glick JA, Graham RS, Voils SA. Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B. Ann Pharmacother. 2010 Jan;44(1):215-8. doi: 10.1345/aph.1M453. Epub 2009 Dec 22. PubMed PMID: 20028954.

[4] La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin. 2009 Jan;25(1):149-60. doi: 10.1185/03007990802611935 . Review. PubMed PMID: 19210148.

[5] Attenello FJ, Mukherjee D, Datoo G, McGirt MJ, Bohan E, Weingart JD, Olivi A, Quinones-Hinojosa A, Brem H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008 Oct;15(10):2887-93. doi: 10.1245/s10434-008-0048-2. Epub 2008 Jul 18. PubMed PMID: 18636295.

6: Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol. 2007 Feb 1;25(4):399-404. PubMed PMID: 17264335; PubMed Central PMCID: PMC2556256.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)